Drug intelligence / Profile preview

SY-12321

Development stage: Phase 2
Lead developer: Shouyao Holdings
Modality: Small Molecules
Administration: Oral

Overview

SY-12321 is an orally bioavailable, small molecule tyrosine kinase inhibitor (TKI) targeting the anaplastic lymphoma kinase (ALK) protein. Developed by First Pharmaceutical Holdings (Beijing), it is currently being evaluated in Phase I/II clinical trials for the treatment of ALK-positive advanced malignancies, including non-small cell lung cancer (NSCLC), inflammatory myofibroblastic tumors, and other ALK-driven solid tumors. The drug is designed to inhibit the signaling pathways activated by ALK fusion proteins or mutations, which drive tumor growth and survival. It is being studied in both ALK TKI-naive patients and those previously treated with other ALK inhibitors.

Targets

ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)

Beyond the preview

Go deeper on SY-12321.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SY-12321.

Explore the full profile